Novartis wins expanded European OK for Cosentyx amid pursuit of $5 billion sales

Novartis on Wednesday won a new European approval for its inflammation drug Cosentyx in a form of arthritis, as the Swiss drugmaker predicts broadening use of its top-selling medicine will eventually push annual sales beyond $5 billion.

from Reuters: Health News https://ift.tt/2yNSnrz